CD226 and COVID-19: An intriguing observation is that in COVID-19 patients with T2D, the NKeff cells subset exhibits an increased presence of inhibitory receptors, specifically KIRs, and a reduced presence of activating receptors DNAM1 (CD226) and NKG2D, as opposed to patients with only COVID-19 or T2D.